A positive Phase 3 readout for Moderna and Merck's personalized mRNA cancer vaccine highlights a potential shift toward genomics-driven immunotherapy. The intismeran autogene therapy with Keytruda improved recurrence-free and distant metastasis-free survival in melanoma, marking the first favorable Phase 3 for an mRNA cancer therapy. This could renew investor interest in ARKG and other genomics-focused ETFs as precision medicine gains traction.
JPMorgan’s healthcare dealmakers say public markets are reopening for biotech, but buyers remain selective. High-quality assets may exit via M&A or IPO through dual-tracks, with Big Pharma funding larger bets. EY notes first-in-class momentum and new financing models, signaling catalysts for ARKG holdings over the next 6–12 months.
